Navigation Links
EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors
Date:9/1/2010

EUSA Pharma Announces the Appointment of Stephen A. Stamp to... -- OXFORD, England and LANGHORNE, Pennsylvania, September 1, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Personnel Announcements Click to view news release full screen  

EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors

 

OXFORD, England and LANGHORNE, Pennsylvania, September 1, 2010 /PRNewswire/ -- EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced the appointment of Stephen A. Stamp to the company's Board as an independent Non-Executive Director.

Mr Stamp has extensive experience of the specialty pharmaceutical sector having previously held Board-level roles at Xanodyne Pharmaceuticals Inc. and Shire Pharmaceuticals Plc, and most recently as Chief Financial Officer of K-V Pharmaceutical Company. Mr Stamp has considerable financial expertise developed during a career spanning over 25 years, including more than 10 years in corporate finance and investment banking. He is an Associate Member of the Institute of Chartered Accountants.

"I want to warmly welcome Stephen to EUSA Pharma," said Rolf Stahel, EUSA Pharma's Chairman. "Since its foundation four years ago, EUSA has established itself as a successful transatlantic specialty pharma business, and is now entering its next phase of rapid and profitable growth. Stephen's financial expertise, and history of success in our industry, will prove an important asset as we transition EUSA into one of the most successful companies in its field."

Commenting on his appointment, Stephen A. Stamp said, "Having witnessed EUSA's impressive growth, I am excited to be helping the company achieve its ambitious plans. Having already built a robust commercial infrastructure in the US and Europe, and a wider global distribution network, I believe EUSA is well placed for future success, and I welcome the opportunity to be part of the company's continued rapid development."

About EUSA Pharma

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight marketed products, including Caphosol(R) for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high dose chemotherapy, Erwinase(R) and Kidrolase(R) for the treatment of acute lymphoblastic leukemia, Collatamp(R) G, a surgical implant impregnated with the antibiotic gentamicin, ProstaScint(R) for imaging the extent and spread of prostate cancer and Quadramet(R) for the treatment of pain in patients whose cancer has spread to the bones. EUSA also has several products in late-stage development.

Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, TVM Capital, NeoMed and NovaQuest. Since its foundation, the company has raised over $300 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Limited, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. Key to its rapid growth strategy is the company's established commercial infrastructure in the US, pan-European presence covering over 20 countries and wider distribution network in a further 80 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing, in line with its ambitious target to become the leading specialty company in its areas of therapeutic and geographic focus.

Contacts Bryan Morton Chief Executive EUSA Pharma Tel: +44(0)1865-784255 Rob Budge RJB Communications Tel: +44(0)1865-760969 Mobile: +44(0)7710-741241
'/>"/>

SOURCE EUSA Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech
2. PharmaNet Development Group Appoints Anthony Maida, Vice President, Clinical Research
3. Reportlinker Adds Advances in Biopharmaceutical Technology in China
4. Access Pharmaceuticals Presents at American Chemical Society Annual Fall Meeting in Boston, MA
5. Archimedes Pharma US Announces New US Headquarters In Bedminster, New Jersey
6. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
7. NanoSmartâ„¢ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology
8. PDL BioPharma Announces Retirement of $61.6 Million of 2.75% Convertible Notes due August 2023 for Common Stock
9. K-V Pharmaceutical Company Engages BDO USA, LLP as Independent Registered Accountants
10. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
11. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 2017  Halozyme Therapeutics, Inc. (NASDAQ: HALO), a ... today announced that an Oncologic Drug Advisory Committee ... 11 to 0 that the benefit/risk of rituximab/hyaluronidase ... for patients in the proposed indications of follicular ... leukemia. The FDA action date is June 26, ...
(Date:3/29/2017)... San Diego, CA (PRWEB) , ... March 29, ... ... that develops cutting edge instrumentation for cell-based assays, disperses a quarterly travel award ... scientific conferences. Today the company announced that its new round of awards ...
(Date:3/29/2017)... ... ... Bactana Animal Health, a company developing natural products aimed at reducing the ... gut microbiota, today announced the closing of its first round of funding. , ... Management, LLC and a number of private investors. The company will use the financing ...
(Date:3/29/2017)... DIEGO and NEWARK, Del. ... , a privately-held regenerative medicine company, and W. ... materials science company, today announced a collaborative research agreement ... novel implantable cell therapy delivery device technologies that provide ... than a decade, ViaCyte has been developing innovative stem ...
Breaking Biology Technology:
(Date:3/22/2017)... 2017 Optimove , provider of ... such as 1-800-Flowers and AdoreMe, today announced two ... Replenishment. Using Optimove,s machine learning algorithms, these features ... replenishment recommendations to their customers based not just ... customer intent drawn from a complex web of ...
(Date:3/16/2017)... 2017 CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution against identity ... Used combined in one project, multi-biometric ... ...
(Date:3/7/2017)... -- Brandwatch , the leading social intelligence company, today announces ... to uncover insights to support its reporting, help direct future campaigns, ... leading youth charity will be using Brandwatch Analytics social listening and ... understanding of the topics and issues that are a priority for ... "Until ...
Breaking Biology News(10 mins):